Keywords: renovis, ph, ii, trial, phn, drug, misses

Renovis' Ph II trial of PHN drug misses endpoint

Article | 14 March 2005

California, USA-headquartered Renovis says it is terminating development of REN-1654 for the treatment of post-herpetic neuralgia after results from a ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Drugs

Alpha

Prolastin

Go to drug listing